Goli samimi (22 Ergebnisse)

Zustand: New.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Zustand: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Zustand: New.

Zustand: New.

Hardcover. Zustand: Brand New. 250 pages. 9.25x7.50x0.67 inches. In Stock.

Hardcover. Zustand: Brand New. 300 pages. 9.00x6.00x0.69 inches. In Stock.

Zustand: New.

Hardback. Zustand: New. New copy - Usually dispatched within 4 working days.

Hardcover. Zustand: new. Hardcover. Gynecologic cancers-including ovarian, endometrial and cervical cancers-account for approximately 100,000 new cases and over 30,000 deaths per year in the United States. The prevention and interception of these cancers would greatly impact outcomes and significantly reduce mortality rates. For ovarian cancer, screening in the general population is not considered effective; therefore, most cases of this cancer are diagnosed at a late stage with a poor survival rate. Endometrial cancer incidence and mortality have been markedly increasing in recent years, due in large part to increasing obesity rates and other lifestyle factors. Cervical cancer has had the benefit of the availability of both screening and prevention. Equity in the dissemination and implementation of these prevention and screening methods is essential for early diagnosis and treatment. These opportunities and challenges related to the diagnosis and high mortality of these gynecologic cancers emphasize the importance of identifying women at higher risk for these cancer types, and providing prevention/interception interventions to decrease incidence and improve outcomes. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Hardcover. Zustand: new. Hardcover. Gynecologic cancers-including ovarian, endometrial and cervical cancers-account for approximately 100,000 new cases and over 30,000 deaths per year in the United States. The prevention and interception of these cancers would greatly impact outcomes and significantly reduce mortality rates. For ovarian cancer, screening in the general population is not considered effective; therefore, most cases of this cancer are diagnosed at a late stage with a poor survival rate. Endometrial cancer incidence and mortality have been markedly increasing in recent years, due in large part to increasing obesity rates and other lifestyle factors. Cervical cancer has had the benefit of the availability of both screening and prevention. Equity in the dissemination and implementation of these prevention and screening methods is essential for early diagnosis and treatment. These opportunities and challenges related to the diagnosis and high mortality of these gynecologic cancers emphasize the importance of identifying women at higher risk for these cancer types, and providing prevention/interception interventions to decrease incidence and improve outcomes. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

Hardcover. Zustand: new. Hardcover. Gynecologic cancers-including ovarian, endometrial and cervical cancers-account for approximately 100,000 new cases and over 30,000 deaths per year in the United States. The prevention and interception of these cancers would greatly impact outcomes and significantly reduce mortality rates. For ovarian cancer, screening in the general population is not considered effective; therefore, most cases of this cancer are diagnosed at a late stage with a poor survival rate. Endometrial cancer incidence and mortality have been markedly increasing in recent years, due in large part to increasing obesity rates and other lifestyle factors. Cervical cancer has had the benefit of the availability of both screening and prevention. Equity in the dissemination and implementation of these prevention and screening methods is essential for early diagnosis and treatment. These opportunities and challenges related to the diagnosis and high mortality of these gynecologic cancers emphasize the importance of identifying women at higher risk for these cancer types, and providing prevention/interception interventions to decrease incidence and improve outcomes. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…

Buch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Gynecologic cancers-including ovarian, endometrial and cervical cancers-account for approximately 100,000 new cases and over 30,000 deaths per year in the United States. The prevention and interception of these cancers would greatly impact outcomes and significantly reduce mortality rates. For ovarian cancer, screening in the general population is not considered effective; therefore, most cases of this cancer are diagnosed at a late stage with a poor survival rate. Endometrial cancer incidence and mortality have been markedly increasing in recent years, due in large part to increasing obesity rates and other lifestyle factors. Cervical cancer has had the benefit of the availability of both screening and prevention. Equity in the dissemination and implementation of these prevention and screening methods is essential for early diagnosis and treatment. These opportunities and challenges related to the diagnosis and high mortality of these gynecologic cancers emphasize the importance of identifying women at higher risk for these cancer types, and providing prevention/interception interventions to decrease incidence and improve outcomes.…

Zustand: new. Questo è un articolo print on demand.

Buch. Zustand: Neu. Gynecologic Cancer | Risk Factors, Interception and Prevention | Buch | Englisch | 2026 | MDPI AG | EAN 9783725877935 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.

Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. 188 pp. Englisch.…

Buch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer.…